Met Life Investment Management, LLC Terns Pharmaceuticals, Inc. Transaction History
Met Life Investment Management, LLC
- $18.1 Billion
- Q1 2025
A detailed history of Met Life Investment Management, LLC transactions in Terns Pharmaceuticals, Inc. stock. As of the latest transaction made, Met Life Investment Management, LLC holds 21,880 shares of TERN stock, worth $66,515. This represents 0.0% of its overall portfolio holdings.
Number of Shares
21,880
Previous 43,760
50.0%
Holding current value
$66,515
Previous $244,000
75.41%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding TERN
# of Institutions
143Shares Held
84.5MCall Options Held
256KPut Options Held
133K-
Soleus Capital Management, L.P. Greenwich, CT8.17MShares$24.8 Million1.87% of portfolio
-
Orbimed Advisors LLC San Diego, CA7.56MShares$23 Million0.65% of portfolio
-
Morgan Stanley New York, NY7.11MShares$21.6 Million0.0% of portfolio
-
Vivo Capital, LLC Palo Alto, CA6.9MShares$21 Million5.17% of portfolio
-
Deep Track Capital, LP Greenwich, CT5.58MShares$17 Million0.54% of portfolio
About Terns Pharmaceuticals, Inc.
- Ticker TERN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 37,613,800
- Market Cap $114M
- Description
- Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical t...